AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04961138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Removing tumor by surgery.
Study NCT03019705 — intervention group
Intervention type: OTHER
Intervention: Observation
Study NCT05480163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement records
Description: Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
Study NCT05480163 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement records
Description: Recordings of spirometry, acoustics, movement (chest volumetry) parameters for FVC and LVC exercises.
Study NCT05442567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion
Study NCT05442567 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Participants will not receive any intervention in the Observational Cohort.
Study NCT06223178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thumb-tack needle
Description: Sterilizing skin and avoiding vessels, the thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The thumb-tack needle will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
Study NCT06223178 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham thumb-tack needle
Description: Sterilizing skin and avoiding vessels, the sham thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The sham device will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
Study NCT06223178 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Basic gynecological treatment
Description: Gynecological health care guidance will be provided as patients needed.
Study NCT06223178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic gynecological treatment
Description: Gynecological health care guidance will be provided as patients needed.
Study NCT06280612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pet therapy
Description: The patients were allowed to spend time with an animal (cat/robotic cat) for 20 minutes twice a week for 12 weeks.
Study NCT05151224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: microRNA 21
Description: Plasma microRNA 21 5p expression, by real-time polymerase chain reaction, before and after neoadjuvant systemic therapy.~Blood sample will be taken by a trained nurse, amount of blood will be 3 ml, and will be taken twice, one time before the start of the neoadjuvant systemic treatment , second time by the end of the neoadjuvant systemic treatment.
Study NCT04904380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active peer learning
Description: HMS, HBS and peer learning in combination with AIR and PRISMS
Study NCT04904380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active peer learning
Description: HMS, HBS and peer learning in combination with AIR and PRISMS
Study NCT03121066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Magnetic Stimulation
Description: The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
Study NCT03121066 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
Study NCT05414149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative intravitreal injections of ranibizumab or conbercept
Description: IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.
Study NCT05414149 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative intravitreal injections of ranibizumab or conbercept
Description: IVR group means patients received intravitreal ranibizumab injections (IVR) (0.5mg/0.05ml) before vitreous surgery. IVC group means patients that received intravitreal conbercept injection (IVC) (0.5mg/0.05ml) before vitreous surgery.
Study NCT05475600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical APA group:
Description: Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
Study NCT05475600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APA with Exergaming device
Description: Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à classical cyclo-ergometer 3 - Cool down 15 to 20min / stretching / Objective: to bring the body back to a resting state
Study NCT05475600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APA associated with biofeedback relaxation
Description: Activity type: aerobic Frequency: 3sessions per week Duration of session: 30 to 60min Intensity: mild to moderate (4-6 on RPE Scale) Session description: 1 - Warm-up 5 to 10min / Activation of devices and systems: muscular, articular, cardiovascular / Objective: preparation of body and mind for physical activity. 2 - Training 10 to 30min physical activity with à Exergaming device 3 - Cool down: 20min / Biofeedback relaxation device / Objective: to bring the body back to a resting state
Study NCT06530108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLISSIT model based sexual health education
Description: the PLISSIT model includes the steps of PLISSIT (P-Permission), LI-Limited Information, SS-Specific Suggestions, IT-Intensive Therapy. This model provides communication with the patient and Since it is a model that increases confidence and provides care interventions based on the patient's preference, it has the feature of guiding sexual education during pregnancy by establishing the bond between the pregnant woman and the midwife.
Study NCT06530108 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PLISSIT model based sexual health education
Description: the PLISSIT model includes the steps of PLISSIT (P-Permission), LI-Limited Information, SS-Specific Suggestions, IT-Intensive Therapy. This model provides communication with the patient and Since it is a model that increases confidence and provides care interventions based on the patient's preference, it has the feature of guiding sexual education during pregnancy by establishing the bond between the pregnant woman and the midwife.
Study NCT05218577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high selenium functional food
Description: HSFF was made from the liver of the cow, that participant could eat HSFF direcly.
Study NCT05218577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium supplement
Description: 20 microgram/day selenium suppplement powder.
Study NCT05218577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo mocaf powder
Study NCT05542446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection.
Study NCT05542446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection.
Study NCT05274412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypotension prediction index(HPI)
Description: Implementing hypotension prediction index (HPI) in perioperative goal-directed hemodynamic therapy. Keep HPI \< 85; pulse pressure variation >12%; keep cardiac index >2L/min/cm\^2; keep mean arterial pressure > 65mmHg.
Study NCT05189132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontal Diagnosis
Description: All participants, in the test group and in the control group, will undergo an initial periodontal evaluation. The clinical evaluation will always be carried out by the same examiner, the author of the study, in order to guarantee calibrated observations. During data collection, intra-observer calibration will be performed, as recommended by the WHO (WHO, 1993), in order to minimize diagnostic variability and verify agreement
Study NCT05189132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological analysis
Description: Microbiological analysis will be performed using a sample of subgingival bacterial plaque. The sample will be collected at the tooth and at the location with the highest probing depth values in each quadrant.~A sterilized paper tip from the microbiological kit will be introduced to the bottom of the bag, with the aid of tweezers, remaining in the same position for 10 seconds. After collecting the sample, the paper tip will be placed in an individual transfer tube, properly identified. Afterwards, the sample will be sent to the laboratory, where a polymerase chain reaction (PCR) test is performed to identify the following bacteria - A. actinomycetemcomitans, T. forsythia, T. denticola, P. gingivalis, P. intermedia and F. nucleatum.
Study NCT05189132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory mediators
Description: The evaluation of inflammatory mediators will be performed with the aid of an absorbent paper strip, which is placed inside the periodontal pocket, for about 30 seconds. The sample will be taken from the tooth that has the highest probing depth values.~The collected sample will be placed and stored in an individual transfer tube properly identified and in accordance with the laboratory's instructions. Afterwards, the sample will be sent to the laboratory, where the ELISA test is performed to quantify the following inflammatory mediators - IL-1β, IL-6 and TNF-α.
Study NCT05274412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ordinary goal-directed hemodynamic therapy
Description: Keep pulse pressure variation >12%; keep cardiac index >2L/min/cm\^2; keep mean arterial pressure > 65mmHg.
Study NCT05138341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) intracranial hemorrhage Evacuation
Description: Patients randomized to MIS group will be undergoing an intervention will get Minimal Invasive Surgical treatment.~The market approved Artemis Device (MIS group) will be used. The Artemis Device, Aspiration Pump, and endoscope are used to rinse (irrigate) this area and to gently suction out the rinsing fluid and any blood or clot in brain. The Device is also designed to prevent clogging during the suction of fluid and blood.
Study NCT06170281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Behavioral Treatment
Description: Migraine Behavioral Treatment involving daily activities
Study NCT04928391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: A single dose of 0.5 µ/kg IV dexmedetomidine at the end of surgery
Study NCT05155917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 UNT/ML [Toujeo]
Description: insulin glargine sc (0.25 U/kg body weight)
Study NCT04928391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: A single dose of 0.1 mg/kg IV nalbuphine at the end of surgery
Study NCT04928391 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Same volume of saline placebo IV at the end of surgery
Study NCT04643366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Neoadjuvant chemotherapy with 2 months of combination oxaliplatin and 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX)
Study NCT04643366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Pelvic Intensity-modulated radiation therapy (IMRT)
Study NCT06376188 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: communication training
Description: The intervention group received a communication training session prior to the prebriefing and familiarization of the scenario, including advice on how to improve communication skills as well as how to create an optimal setting for difficult medical conversations. This communication training session has been created on the basis of an in-depth literature research.(Brock et al., 2019; Chumpitazi et al., 2016; Collins et al., 2018; Grant et al., 2016; Tobler et al., 2014; Vaidya et al., 1999; Yuan et al., 2019)
Study NCT06099366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate
Description: vincristine 1.5mg/m2 L-asparaginase 6,000U/m2 Dexamethasone 6mg/m2 Intrathecal Cytarabine Intrathecal Methotreate
Study NCT00663624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspart insulin
Description: subcutaneous aspart insulin every 2 hours
Study NCT00663624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual care as prescribed by the ED physicians.
Description: Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
Study NCT05809323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention Group
Description: Patients will be educated on methods of self-evaluating exertion and cardiovascular effort by assessing respiratory rate and perceived exertion. Next, patients will be given options for cardiovascular activities and complete at a moderate level of activity for a minimum of 150 minutes per week. Patients will perform a combination of exercises under the supervision of a physical therapist until a mod intensity level is reached and sustained. Patients will be taught to use the activity tracker to record their heart rate, activity, and PES. Patients will have a phone call every week to assess status, answer questions, and provide guidance on progressing intensity or duration of exercise. At the end of 12 weeks all patients will return for re-assessment.
Study NCT05536154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Day 1\~Day 2: 75mg/m\^2
Study NCT05536154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Day 1\~Day 2: 200mg/m\^2, q12h
Study NCT05536154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: Day 6: 6mg
Study NCT05809323 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Patients in the control group will be instructed to continue with baseline physical activities over the duration of the study and be given instructions on the use of the activity tracker. At the end of 12 weeks all patients will return for re-assessment.
Study NCT05772442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Extra blood samples (5-10 mL) drawn
Description: Extra blood samples will be sent for metabolomics analysis.
Study NCT04939779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 tablet 400mg (Test drug, Batch# 3183817R)
Description: Oral administration
Study NCT04939779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 tablet 400mg (Reference drug, Batch# 1650006)
Description: Oral administration
Study NCT00175162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopal G vs. Refobacin-Palacos R bone cement
Description: Bone cement
Study NCT06099366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000U/m2 Intrathecal Methotrexate
Study NCT06099366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Mecaptopurine 50mg/m2 Cyclophosphamide 1,000mg/m2 Cytarabine 75mg/m2 L-asparaginase 6,000IU/m2 Intrathecal Methotrexate
Study NCT05463172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal strengthening exercises
Description: abdominal strengthening exercises
Study NCT05463172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscles strengthening exercises
Description: to strengthen pelvic floor muscles
Study NCT05474872 — intervention group
Intervention type: DEVICE
Intervention: BIS monitoring
Description: The depth of anesthesia will be monitored using Bispectral Index values.
Study NCT06099366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Intrathecal Methotrexate
Study NCT06099366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate
Description: Vincristine 1.5mg/m2 Methotrexate 5,000mg/m2 Mecaptopurine: 25mg/m2 Intrathecal Methotrexate
Study NCT04435561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy rehabilitation and dry needling
Description: The dry needling group receives 6 sessions of dry needling in the spastic muscles of the upper and lower hemiparetic limbs.
Study NCT04435561 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard physiotherapy rehabilitation
Description: This group receives their traditional intervention, without dry needling.
Study NCT05552859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL
Description: Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
Study NCT05552859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec 100 U/mL
Description: Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
Study NCT05611515 — intervention group
Intervention type: PROCEDURE
Intervention: TORS
Description: * Arm 1: Intensity-Modulated Radiation Therapy (IMRT)~* Arm 2: Trans-oral Laser Microsurgery (TLM)~* Arm 3: Trans-oral Robotic Surgery (TORS)